GenomicsFund.com Debuts as Top Performing Mutual Fund in June Quarter Lipper
and Morningstar Report Second Quarter Gain of 39.01% Compared With Decline of
2.66% By S&P 500 and Decline of 13.26% for NASDAQ Composite
GAITHERSBURG, Md., Jul 10, 2000 /PRNewswire via COMTEX/ -- With a gain of
39.01% in the second quarter ended June 30, GenomicsFund.com (Nasdaq: GENEX),
reported today that it topped all mutual funds according to both Lipper, Inc.
and Morningstar Data Services. During the same period the S&P 500 Index declined
2.66% while the NASDAQ Composite fell 13.26%.
GenomicsFund.com is the world's first and only mutual fund specializing in the
new genomics industry.
Commenting on the performance, portfolio manager Steve Newby said, "Our gain was
powered by the strong advances in Millennium Pharmaceuticals (Nasdaq: MLNM),
Human Genome Sciences (Nasdaq: HGSI), Aurora Biosciences (Nasdaq: ABSC), and
Protein Design Labs (Nasdaq: PDLI)."
"And," Mr. Newby noted, "the recent announcement by Celera Genomics (CRA) having
completed the sequencing of the human genome could provide additional impetus to
this emerging highly volatile market sector." Mr. Newby cautioned that past
performance may not be indicative of future results, and that potential
investors should read the prospectus carefully before investing. He suggested
visiting the Fund's website for more information about the genomics industry and
the companies in the field: genomicsfund.com.
GenomicsFund.com is a no-load fund and requires a minimum initial investment of
$5,000. For more information, visit the Fund's website at:
genomicsfund.com or call 1-877-433-Gene.
Past performance cannot guarantee future results. Investment return and share
price will fluctuate and redemption value may be more or less than original
cost. The prospectus contains complete information, including management fees,
expense and special risk considerations. Read the prospectus carefully before
you invest or send money.
SOURCE GenomicsFund.com
CONTACT: Steven T. Newby, Chief Investment Officer of GenomicsFund.com
800-395-0495; or Irving L. Straus, Chairman of Straus Corpora
e
Communications, 212-768-2477, for GenomicsFund.com
URL: genomicsfund.com |
